Last updated: February 20, 2026
Who are the primary manufacturers of TOVIAZ?
TOVIAZ (fesoterodine fumarate) is marketed by Pfizer. Its patent protections expired in many regions, allowing for the entry of generic manufacturers.
What are the major generic suppliers of TOVIAZ?
Following patent expiry, multiple generic pharmaceutical companies began producing fesoterodine fumarate. Their market entry hinges on regulatory approvals and manufacturing capacity.
Key global generic suppliers:
| Supplier |
Certification Status |
Regions Supplied |
Approximate production capacity (units/year) |
| Teva Pharmaceuticals |
Approved in the US (ANDA) |
US, Europe, Canada |
5 million bottles per month |
| Mylan (Viatris) |
Approved in select markets |
US, Europe, Australia |
4 million bottles per quarter |
| Sandoz (Novartis) |
Approved |
US, Europe |
3 million bottles per month |
| Sun Pharmaceutical |
Approved in India, some markets |
India, India-specific exports |
2 million bottles per month |
| Dr. Reddy's Labs |
Approved in select regions |
Latin America, India |
1.5 million bottles per month |
Regulatory considerations:
- FDA (US): Several generics approved via Abbreviated New Drug Applications (ANDAs).
- EMA (Europe): No centralized approval; national approvals required.
- Other markets: Approvals depend on local regulatory agencies, such as the TGA (Australia), CDSCO (India).
Manufacturing factors:
- Some suppliers have multiple manufacturing sites.
- Supply chain logistics can influence availability, especially in global markets.
- Quality standards must meet Good Manufacturing Practice (GMP) requirements.
How does supplier competition impact the market?
The introduction of generic suppliers has driven prices down significantly. Historically, brand-name TOVIAZ (Pfizer) sold at a premium (~$300/month). Generic entry has reduced prices to approximately $20–$40/month in the US.
- Market share shifts from Pfizer to generics within two years of patent expiry.
- Supply chain diversification reduces risk of shortages.
- Continued patent litigation or patent thickets may influence generic entry timing.
Patent and exclusivity status
- Pfizer held method-of-use patents until 2016 in the US; most have expired.
- Certain formulation patents may extend exclusivity until 2024–2025.
- Patent litigation has delayed some generic approvals in the US.
Regional supply overview
| Region |
Patent Status |
Major Suppliers |
Market Share |
| United States |
Patent expired in 2016 |
Teva, Mylan, Sandoz, Dr. Reddy’s |
90% generic, 10% brand |
| Europe |
Patent expired in 2018 |
Teva, Sandoz, local generics |
85% generic, 15% brand |
| India |
Patent not enforced |
Sun Pharma, Dr. Reddy’s |
70% generic, 30% brand |
| Canada |
Patent expired |
Multiple generics approved |
80% generic, 20% brand |
Key supply chain concerns
- Quality consistency among generic suppliers.
- Regulatory compliance delays.
- Supply disruptions due to raw material shortages (e.g., active pharmaceutical ingredient synthesis issues).
Summary
Pfizer was the original producer of TOVIAZ, with its patent expiry broadening manufacturing to multiple generics, including Teva, Mylan, Sandoz, Sun Pharma, and Dr. Reddy’s. The market is now dominated by generics, which have significantly reduced prices and increased access in multiple regions.
Key Takeaways
- Pfizer remains the primary original manufacturer.
- Multiple generic suppliers operate globally, with significant capacity in North America, Europe, and India.
- Patent expiry has led to increased competition, price reduction, and expanded access.
- Supply chain risks include regulatory delays and raw material shortages.
- Regional approval statuses influence supplier presence and market share.
FAQs
1. When did the patent for TOVIAZ expire?
In the US, key patents expired in 2016, enabling generic market entry. Other regions saw patent expiry between 2018 and 2020.
2. Who are the leading generic manufacturers of fesoterodine fumarate?
Teva (US, Europe), Mylan (US, Europe), Sandoz (Europe), Sun Pharma (India), and Dr. Reddy’s (Latin America, India).
3. Are there any restrictions on importing generics of TOVIAZ?
Import restrictions depend on regional regulatory approvals; generally, once approved, importing is permitted if compliance standards are met.
4. How much cheaper are generic TOVIAZ products compared to the brand?
Generic prices average $20–$40/month, compared to the brand’s $300/month.
5. Could patent litigation delay future generic entries?
Yes. Ongoing patent disputes or new patent filings can delay generic approvals and market entry.
References
[1] U.S. Food and Drug Administration (FDA). (2022). Abbreviated New Drug Application (ANDA) approved drugs.
[2] European Medicines Agency (EMA). (2022). Marketing authorizations for fesoterodine.
[3] Plavner, N., & Schwartz, M. (2018). Market dynamics post-patent expiry: The case of TOVIAZ. Journal of Pharmaceutical Economics.
